Source disclosure: February 12, 2026
Meiji Holdings Co., Ltd. [2269.T]
TOKYO, Feb 12 (Pulse News Wire) – Meiji Holdings CO.,LTD. (2269.T) corrected certain sections of its past financial reports due to errors identified after their release.
The corrections affect the supplementary explanations for the fiscal years ending March 2025 and March 2026. The company noted that there were no numerical data changes; the adjustments pertain solely to textual descriptions. Specifically, three areas within the pharmaceutical segment's sales figures for the third quarter of fiscal year 2025 have been revised: 1. Sales performance of key products in the pharmaceutical segment for the third quarter of fiscal year 2025. 2.
Year-over-year growth rate of key product sales in the pharmaceutical segment for the third quarter of fiscal year 2025. 3. Progress towards annual plan targets for key product sales in the pharmaceutical segment for the third quarter of fiscal year 2025. These corrections reflect minor adjustments in reported figures, such as reducing the human vaccine sales figure from ¥301 billion to ¥300 billion and adjusting the corresponding percentage increases accordingly. The revisions aim to ensure the accuracy and integrity of the company’s financial communications.
Investors and stakeholders should review the updated documents for precise details.
AI-translated content. 🟢 Confidence: High See terms • Original filing